As science has rapidly progressed, more and more therapies targeting an unmet medical need in the treatment of serious or life-threatening conditions have been introduced. To assist patients with life-threatening conditions and shorten timelines between the development of these new therapies and patients receiving treatment, the FDA has introduced an expedited review program. But, how can you know if you are qualified for an expedited review program and, if it is always the best path for your development?
Join Cato Research in our upcoming webinar to learn how to qualify for this new program, better understand both advantages and risk of an expedited development, and get answers from experts to your questions.
Greg Hileman, Ph.D., VP of Regulatory Strategy, Cato Research, will guide you through the process of expedited development and Will Lee, Ph.D., R.A.C., VP of Regulatory Affairs, Cato Research, will be in attendance for questions and answers.